Loading…
Public Option Deficit Reduction Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
51pct
1d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Public Option Deficit Reduction Act This bill requires the Department of Health and Human Services (HHS) to offer a public health insurance option through the health insurance exchange. Unlike the coverage options currently available on the exchange, which are administered by private insurance companies, this public option must be administered directly by HHS. The public option must comply with the same general requirements as other plan types available on the exchange, including with respect to available benefits, benefit levels, provider networks, notices, consumer protections, and cost sharing. Medicare health care providers are automatically participants in the public option unless they opt out, and providers not participating in Medicare may opt in. In addition, the bill establishes requirements for setting premiums, payment rates, and provider incentives. The bill appropriates funds to establish the public health insurance option, which HHS must repay over 10 years.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2019 · fourth_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting S. 2247, Phair Relief Act of 2019 (Kennedy)-transparency around price concessions for drugs S. 2387, We Protect American Investment in Drugs Act (Van Hollen)-drug pricing S. 2543, Prescription Drug Pricing Reduction Act of 2019 (Grassley)-Drug pricing S. 2740, Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 (Isakson) - regulations re nonprescription drugs that are marketed without an approved new drug application S. 3052, United States-Mexico-Canada Agreement Implementation Act (Grassley) - drug pricing S. 3067, Non-Opioids Prevent Addiction In the Nation Act (Capito) - non-opioid treatments S. 3092, Expanding Access to Low-Cost Generics Act of 2019 (Smith) - exclusivity period H.R. 3, Lower Drug Costs Now Act of 2019 (Pallone)-drug pricing H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products H.R. 3805, Prescription Drug Rebate Reform Act of 2019 (Gallagher)- drug rebates H.R. 3927, PDMPs Help Patients Act of 2019 (McKinley)-integrating SUDs and behavioral health into PDMPs H.R. 3947, Competition Prescription Act of 2019 (Meadows)- drug pricing H.R. 4010, Emergency Access to Insulin Act of 2019 (Craig)- drug pricing H.R. 4106, Responsibility in Drug Advertising Act of 2019 (DeLauro)-transparency in drug pricing H.R. 4244, MAGIC Act (Kelly)-pathways for insulin approval H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (Cicilline)-drug pricing H.R. 4455, BIOSIM Act (Schrader)-access to biosimilars H.R. 4460, Turn the Tide Act (Kuster)-Opioids H.R. 4538, Closing Loopholes for Orphan Drugs Act (Welch)-Access to drugs H.R. 4640, Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 (DeFazio) - direct negotiation H.R. 4712, Fairness in Orphan Drug Exclusivity Act (Dean) - limitations on exclusive approval of orphan drugs H.R. 4810, Opioid Prescription Verification Act of 2019 (David) - dispensing of controlled substances H.R. 4906, Insulin Price Reduction Act (Diana DeGette) - insulin costs H.R. 5304, PBM Transparency in Prescription Drug Costs Act (Schrader) - PBMs H.R. 5364, End Price Gouging for Insulin Act (Beatty) - annual reference price for insulin products H.R. 5430, United States-Mexico-Canada Agreement Implementation Act (Hoyer) - drug pricing H.R. 5442, Lowest Price for Patients Act (Porter) - pharmacies to disclose any differential between the cost of a prescription drug H.R. 5444, Lower Insulin Costs Now Act (Underwood) - lowering insulin costs H.Con.Res. 55, Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements. (Burgess)-drug pricing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $2,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
2019 · fourth_quarter · Medicare/Medicaid
Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products. H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Safety of imported drug components - no specific bill Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Comprehensive gun control legislation Medicare/Medicaid S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections Changes to MACRA - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Publications Open access to information based on publicly funded research Regulations Executive Order entitled, "Protecting and Improving Medicare for our Nation's Seniors." CMS- Proposed changes to Medicaid Funding
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · fourth_quarter · Health Issues
Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products. H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Safety of imported drug components - no specific bill Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Comprehensive gun control legislation Medicare/Medicaid S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections Changes to MACRA - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Publications Open access to information based on publicly funded research Regulations Executive Order entitled, "Protecting and Improving Medicare for our Nation's Seniors." CMS- Proposed changes to Medicaid Funding
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting S. 2247, Phair Relief Act of 2019 (Kennedy)-transparency around price concessions for drugs S. 2387, We Protect American Investment in Drugs Act (Van Hollen)-drug pricing S. 2543, Prescription Drug Pricing Reduction Act of 2019 (Grassley)-Drug pricing H.R. 3, Lower Drug Costs Now Act of 2019 (Pallone)-drug pricing H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products H.R. 3805, Prescription Drug Rebate Reform Act of 2019 (Gallagher)- drug rebates H.R. 3927, PDMPs Help Patients Act of 2019 (McKinley)-integrating SUDs and behavioral health into PDMPs H.R. 3947, Competition Prescription Act of 2019 (Meadows)- drug pricing H.R. 4010, Emergency Access to Insulin Act of 2019 (Craig)- drug pricing H.R. 4106, Responsibility in Drug Advertising Act of 2019 (DeLauro)-transparency in drug pricing H.R. 4244, MAGIC Act (Kelly)-pathways for insulin approval H.R. 4398, Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 (Cicilline)-drug pricing H.R. 4455, BIOSIM Act (Schrader)-access to biosimilars H.R. 4460, Turn the Tide Act (Kuster)-Opioids H.R. 4538, Closing Loopholes for Orphan Drugs Act (Welch)-Access to drugs H.Con.Res. 55, Expressing the sense of Congress on the need to inform American consumers with more balanced purchasing information for prescription drugs through the disclosure of price information in direct-to-consumer (DTC) advertisements. (Burgess)-drug pricing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
Client expense: $2,110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Treasury, Dept of, White House Office
2019 · third_quarter · Health Issues
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Proposed Changes to 42 CFR, Part 2 - no specific bill Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Regulatory Issues Docket ID HHS-OCR-2019-0007, RIN 0945-AA11, Nondiscrimination in Health and Health Education Programs or Activities File Code CMS-1715-P; Medicare Program: CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA32 Confidentiality of Substance Use Disorder Patient Records 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA30 Confidentiality of Substance Use Disorder Patient Records: Proposed Changes to 42 CFR Part 2
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2019 · third_quarter · Medicare/Medicaid
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing H.R. 3502 - Protecting People from Surprise Medical Bills Act S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R. 2000 - Medicare-X Choice Act of 2019 S. 296, H.R. 2150 - Home Health Care Planning Improvement Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Proposed Changes to 42 CFR, Part 2 - no specific bill Prior Authorization H.R. 3170 - Improving Seniors Timely Access to Care Act of 2019 Regulatory Issues Docket ID HHS-OCR-2019-0007, RIN 0945-AA11, Nondiscrimination in Health and Health Education Programs or Activities File Code CMS-1715-P; Medicare Program: CY 2020 Revisions to Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies; Medicare Shared Savings Program Requirements; Medicaid Promoting Interoperability Program Requirements for Eligible Professionals; Establishment of an Ambulance Data Collection System; Updates to the Quality Payment Program; Medicare Enrollment of Opioid Treatment Programs and Enhancements to Provider Enrollment Regulations Concerning Improper Prescribing and Patient Harm; and Amendments to Physician Self-Referral Law Advisory Opinion Regulations 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA32 Confidentiality of Substance Use Disorder Patient Records 42 CFR Part 2 [SAMHSA-4162-20]RIN 0930-AA30 Confidentiality of Substance Use Disorder Patient Records: Proposed Changes to 42 CFR Part 2
2019 · second_quarter · Pharmacy
S. 61, Safe and Affordable Drugs from Canada Act (Grassley) - drug importation S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 440, Preserving Access to Cost-Effective Drugs Act (Cotton) - sovereign immunity and Inter Partes Review process S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years Act (Cassidy) - preventing evergreening of patent protections S. 1224, Stop STALLING Act (Klobuchar) - citizen petition process S. 1227, Prescription Pricing for the People Act (Grassley) - FTC report on role of PBMs and allegations of anticompetitive conduct by manufacturers of sole-source drugs S. 1384, Prescription Drug Rebate Reform Act (Romney-Braun) - prescription drug cost sharing S. 1416, Affordable Prescriptions for Patients Act (Cornyn) - product hopping, patent thickets S. 1664, Prescription Drug Price Reporting Act (Scott) - prescription drug price reporting H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 478, Safe and Affordable Drugs from Canada Act (Pingree) - drug importation H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2087, Drug Price Transparency Act (Doggett) - reporting of drug pricing data under Medicare Part B H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting Act (Neal) - transparency in drug pricing H.R. 2115, Public Disclosure of Drug Discounts Act (Spanberger) - disclosure of negotiated Rx discounts H.R. 2279, Safe Step Act (Ruiz) - exceptions process for medication step therapy H.R. 2296, FAIR Drug Pricing Act (Schakowsky) - transparency requirements and justification for high list prices and drug price increases H.R. 2374, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Jeffries) - citizen petition process H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act (Nadler) - prohibiting pay-for-delay agreements H.R. 2376, Prescription Pricing for the People Act (Collins) - FTC study on role of PBMs and competition and transparency in pharmaceutical supply chain H.R. 3379, Price Relief, Innovation, and Competition for Essential Drugs Act (Schakowsky) - exclusivity period for biological products Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2019 · second_quarter · Medicare/Medicaid
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R.2000 - Medicare-X Choice Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Regulatory Issues 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program. (RIN: 0955-AA01 CFR:45 CFR Parts 170 and 171; Federal Register Number:2019-02224) CMS - Problems with prior authorization
2019 · second_quarter · Health Issues
Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Surprise Billing S. 1895 - Lower Health Care Costs Act H.R. 3630 - No More Surprises Act H.R. 3502 - Protecting People From Surprise Medical Bills Act S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R.2000 - Medicare-X Choice Act of 2019 ACA Protections H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder H.R. 2734 - Safer Prescribing of Controlled Substances Act - Federal Prescriber Education Mandates S. 1365, H.R. 2569 - Comprehensive Addiction Resources Emergency Act of 2019 Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Maternal Mortality H.R. 2602 - Healthy MOMMIES Act - extending Medicare ACA coverage and access to maternity care Recommendations to address racial disparities and social determinants in the national maternal mortality crisis Mental Health S. 1576, H.R. 2874 - Behavioral Health Coverage Transparency Act Regulatory Issues 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT Certification Program. (RIN: 0955-AA01 CFR:45 CFR Parts 170 and 171; Federal Register Number:2019-02224) CMS - Problems with prior authorization
2019 · first_quarter · Pharmacy
S. 64, Preserve Access to Affordable Generics and Biosimilars Act (Grassley-Klobuchar) - prohibiting pay-for-delay settlements S. 73, End Taxpayer Subsidies for Drug Ads Act (Shaheen) - prohibiting tax deduction for DTC advertising expenses S. 102, Prescription Drug Price Relief Act (Sanders) - reforms linked to international pricing S. 340, CREATES Act (Leahy) - removing barriers to generic drugs S. 344, Hatch-Waxman Integrity Act (Tillis) - inter partes review process S. 366, FLAT Prices Act (Durbin) - reforms for drugs with sudden price spikes S. 378, Stop Price Gouging Act (Durbin) - excise tax for drugs that have price spikes S. 474, SPIKE Act (Wyden) - justification for drug price increases S. 476, Creating Transparency to Have Drug Rebates Unlocked Act (Wyden) - drug price transparency S. 637, CURE High Drug Prices Act (Blumenthal) - remedies for price gouging S. 657, Point of Sale Rebates (Braun) S. 659, Biologic Patent Transparency Act (Collins) - patent disclosure requirements S. 660, Efficiency and Transparency in Petitions Act (Braun) - FDA citizen petition process S. 844, Short on Competition Act (Klobuchar) - remedies for marginally competitive drug markets S. 977, Transparency Drug Pricing Act (Scott) - transparency and drug pricing reforms H.R. 465, Prescription Drug Price Relief Act (Khanna) - reforms linked to international pricing H.R. 938, BLOCKING Act (Schrader) - changes to 180-day period of market exclusivity for first generic applicant H.R. 965, CREATES Act (Cicilline) - removing barriers to generic drugs H.R. 985, FAST Generics Act (Welch) - removing barriers to generic drugs H.R. 990, Hatch-Waxman Integrity Act (Flores) - inter partes review process H.R. 1093, Stop Price Gouging Act (Pocan) - excise tax for drugs that have price spikes H.R. 1188, FLAT Prices Act (Golden) - reforms for drugs with sudden price spikes H.R. 1344, Competitive DRUGS Act (Doggett) - prohibiting pay-for-delay agreements H.R. 1419, Public Option Deficit Reduction Act (DeFazio) - public option H.R. 1499, Protecting Consumer Access to Generic Drugs Act (Rush) - prohibiting pay-for-delay agreements H.R. 1503, Orange Book Transparency Act (Kelly) - removal of invalidated patents from Orange Book H.R. 1506, FAIR Generics Act (Barragan) - changes to 180-day period of market exclusivity for first generic applicant H.R. 1520, Purple Book Continuity Act (Eshoo) - access to updated information on biologics and biosimilars H.R. 2038, State-Based, Market-Oriented Prescription Drug Negotiations Act (Meadows) - drug price negotiations H.R. 2064, Sunshine for Samples Act (Chu) - reporting requirements on drug samples H.R. 2069, SPIKE Act (Horsford) -justification for drug price increases H.R. 2113, Prescription Drug STAR Act (Neal)-drug price transparency Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to prescription drug rebates; issues relating to prescription drug price blueprint; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2019 · first_quarter · Health Issues
Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019 - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill Transparency of Pharmaceutical prices including all sectors, Pharma Companies, PMBs, Insures, Hospitals and Physicians - no specific bill Pay for Delay - no specific bill Surprise Billing S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R.2000 - Medicare-X Choice Act of 2019 ACA Protections - no specific bill Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder Federal Prescriber Education Mandates - no specific bill Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Regulatory Issues 45 CFR Parts 170 and 171 - RIN 0955-AA01- 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT
2019 · first_quarter · Medicare/Medicaid
Prescription Drugs S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019 - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill Transparency of Pharmaceutical prices including all sectors, Pharma Companies, PMBs, Insures, Hospitals and Physicians - no specific bill Pay for Delay - no specific bill Surprise Billing S. 967 - Resolving Unanticipated Bills Act Gun Violence H.R. 8, S. 42 Background Checks of 2019 - Legislation to close loopholes in background checks for guns S. 184, H.R. 674 Gun Violence Prevention Research Act - Legislation to authorize CDC funds into prevention gun violence research LABOR-HHS Appropriations to fund gun violence research Medicare for All S. 1129 - A bill to establish a Medicare-for-all national health insurance program H.R.1384 - Medicare for All Act of 2019 S. 470 - Medicare at 50 Act H.R. 1346 - Medicare Buy-In and Health Care Stabilization Act of 2019 H.R. 1419 - Public Option Deficit Reduction Act S. 981, H.R.2000 - Medicare-X Choice Act of 2019 ACA Protections - no specific bill Physician Burnout - no specific bill EMR Interoperability & Usability - no specific bill Social Determinants of Health Increased federal funds for community-based food programs which provide medically tailored meals to poor, sick, immobile patients and their families - no specific bill Opioids and Substance Use Disorder Federal Prescriber Education Mandates - no specific bill Federal grants for access to pain experts - no specific bill Changes to MACRA - no specific bill Blocking Granting Medicaid - no specific bill Changes to the Sunshine Act regarding reporting of bulk reprints, textbooks and other peer reviewed education materials - no specific bill Changes to Title X program - no specific bill Regulatory Issues 45 CFR Parts 170 and 171 - RIN 0955-AA01- 21st Century Cures Act: Interoperability, Information Blocking, and the ONC Health IT
| Democratic |
| TN |
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $2,210,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $2,880,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Council of Economic Advisers (CEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE